Fig. 9
From: Platelet-membrane-biomimetic nanoparticles for targeted antitumor drug delivery
In vivo antitumor efficacy of different bufalin formulations in H22-tumor bearing ICR mice. a H22 tumor growth curves after intravenous injection the formulations. Error bars indicate SD (n = 5). b Representative images of tumors isolated after treatment for 16 days (1: PBS; 2: free bufalin; 3: CS-pPLGA/Bu NPs; 4: PLTM-CS-pPLGA/Bu NPs). c Mean weights of the H22 tumors isolated on day 16. d Body weight changes over the 16 days of the experiment (mean ± SD, n = 5)